Quantumzyme denounces unauthorized promotions amid caveat emptor designation

In San Diego, California, on April 30, 2025, Quantumzyme Corp., a biotechnology company that specializes in computational enzyme engineering, announced its ongoing communication with OTC Markets Group regarding the imposition of a 'Caveat Emptor' designation on its securities. This designation suggests to potential investors that the company's stock may pose greater risks or concerns. In response, Quantumzyme has emphasized its commitment to regulatory compliance, asserting its intention to address the issues that led to this designation promptly and thoroughly. The management acknowledged the challenges that come with such a status but reaffirmed their focus on maintaining the integrity of the market and their relationships with shareholders. Furthermore, the company unequivocally denied any connection to reports of unauthorized promotional activities, specifically SMS text messages that mentioned Quantumzyme without its consent. They clarified that these promotional efforts were neither endorsed nor authorized by the company, strongly condemning such actions as harmful to their corporate reputation. Naveen Kulkarni, the Chief Executive Officer of Quantumzyme, articulated the company's position, indicating that they take the matter of regulatory compliance very seriously and are committed to protecting their reputation. The firm aims to reassure its shareholders and the public by maintaining transparent communication throughout this incident. This proactive stance includes open dialogue with regulatory bodies to resolve any misunderstandings or concerns surrounding the company's stock. Despite the current challenges, Quantumzyme remains focused on its business strategy, prioritizing the execution of their operational goals, which involve delivering biocatalysis solutions that enhance sustainability within industrial processes. Their innovative approach combines computational modeling with practical lab validation, allowing them to offer end-to-end enzyme development services that empower their partners. The company envisions that its commitment to eco-friendly solutions will soon establish biocatalysis as the industry standard, driving broader applications for sustainable practices in biotechnology.